Search clinical trials for: Factor VIII-Fc Fusion Protein

Total 54135 results

Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Myeloma Canada

Recruiting

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada
Jiangsu Gensciences lnc.

Recruiting

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Severe Hemophilia A

China
Jiangsu Gensciences lnc.

Not yet recruiting

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Severe Hemophilia A

China
Beijing Hospital
Changhai Hospital; Xiangya Hospital of Central South University; Peking University... and other collaborators

Not yet recruiting

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Connective Tissue Diseases | Thrombocytopenia

China
Lihua Duan

Not yet recruiting

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout

Acute Gout

China
Children's Hospital of Philadelphia
Jazz Pharmaceuticals; Stand Up To Cancer

Recruiting

Lurbinectedin in FET-Fused Tumors (LiFFT)

Ewing Sarcoma | Pediatric Cancer | Desmoplastic Small Round Cell Tumor | Undifferentiated Sarcoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
StemlineTherapeutics, Inc.

Recruiting

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (GO-TAG)

Acute Myeloid Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditions

United States
Sichuan Clover Biopharmaceuticals, Inc.

Recruiting

A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

Chemotherapy-induced Thrombocytopenia (CIT)

China
The First Affiliated Hospital of Xiamen University

Recruiting

Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients (LORMYF)

Rheumatoid Arthritis

China
National Cancer Institute (NCI)

Recruiting

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Lynch Syndrome

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Embryonal Rhabdomyosarcoma | Fusion-Negative Alveolar Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma

United States, Australia, Canada, New Zealand
Beijing VDJBio Co., LTD.

Recruiting

Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects

Health Volunteer

China
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Multiple Myeloma

United States, Spain, France, Greece
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
University of Texas Southwestern Medical Center

Recruiting

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Hemophilia A | Factor VIII

United States
Luye Pharma Group Ltd.
Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor)

Not yet recruiting

A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

Age Related Macular Degeneration
Consorzio Oncotech

Recruiting

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Italy
Immunocore Ltd

Recruiting

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Select Advanced Solid Tumors

United States, Belgium, Korea, Republic of, Australia, Germany, United Kingdom, Spain, Poland, Austria, Brazil, Canada, New Zealand, France, Italy, Netherlands, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Takeda; Amgen

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | t(9;22) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | BCR-ABL1...

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma

United States
EVIVE Biotechnology
Fudan University

Completed

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | t(9;22) | BCR-ABL1 Fusion Protein Expression

United States
Oncoimmune, Inc., a subsidiary of Merck & Co.,...
National Cancer Institute (NCI); University of Michigan Rogel Cancer Center; Ohio... and other collaborators

Completed

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Leukemia | Hematopoietic Stem Cell Transplantation | Graft Versus Host Disease

United States
M.D. Anderson Cancer Center
AstraZeneca; Aravive Biologics Inc

Active, not recruiting

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); National Marrow Donor Program; Blood and Marrow...

Completed

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Multiple Myeloma

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Massachusetts General Hospital
Transplant Genomics, Inc.; CareDx

Completed

Immune Monitoring to Facilitate Belatacept Monotherapy

Kidney Transplant Rejection | Immunosuppression

United States
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
Takeda

Active, not recruiting

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

United States, China, Spain, Australia, Canada, Argentina, Korea, Republic of, Brazil, Japan, Italy, Mexico, France, Greece, Poland, Russian Federation, Austria, Taiwan, Bulgaria, Finland, Turkey
Philogen S.p.A.

Terminated

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Philogen S.p.A.

Terminated

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Myeloid Leukemia, Relapsed, Adult

Germany
RemeGen Co., Ltd.

Completed

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Moderate and Severe RheumatoId Arthritis

China
Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Hemophilia A

China
University of California, Irvine
Amgen

Completed

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

Psoriasis

United States
Bioverativ, a Sanofi company

Completed

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A (XTEND-1)

Factor VIII Deficiency

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Spain, Taiwan, United Kingdom
Jiangsu Gensciences lnc.

Completed

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States
Livzon Pharmaceutical Group Inc.

Completed

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (COVID-19)

COVID-19 Pandemic

Malaysia, Pakistan
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (COVID-19)

COVID-19 Pandemic

Philippines, Indonesia, Russian Federation
Spanish Breast Cancer Research Group
GlaxoSmithKline

Completed

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Breast Cancer

Spain
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
CytoDyn, Inc.
Amarex Clinical Research

Completed

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Incyte Corporation; Celldex Therapeutics

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
Celgene

Terminated

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)

Multiple Myeloma

United States, Canada, Spain, Italy, Denmark, United Kingdom, Belgium, Sweden, Germany
OncoImmune, Inc.

Terminated

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (CATHY)

Acute Graft Versus Host Disease | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Hematopoietic Stem Cell Transplantation

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent... and other conditions

United States

Search clinical trials for: Factor VIII-Fc Fusion Protein

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations